Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation

European Journal of Immunology

Volumn 44, Issue 3, 2014, Pages 774-784

  Wälchli, Sébastien ^a,b   Kumari, Shraddha ^a,b   Fallang, Lars Egil ^a   Sand, Kine M K ^b   Yang, Weiwen ^a,b   Landsverk, Ole J B ^b   Bakke, Oddmund ^b   Olweus, Johanna ^a,b   Gregers, Tone F ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Antigen presentation processing; MHC; Vaccination

Indexed keywords

CD20 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; MELAN A; MESSENGER RNA; PROTEASOME; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENIC VARIATION; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOSOME; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ANTIGEN PRESENTATION/PROCESSING; CD8+ T CELLS; MHC; VACCINATION;

ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENDOSOMES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN TRANSPORT; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84896030409     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343671     Document Type: Article

References (55)

1. Bakke, O. and Dobberstein, B., MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990. 63: 707-716.
2. Wu, T. C., Guarnieri, F. G., Staveley-O'Carroll, K. F., Viscidi, R. P., Levitsky, H. I., Hedrick, L., Cho, K. R. et al., Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. U. S. A. 1995. 92: 11671-11675.
3. Parra-Lopez, C. A., Lindner, R., Vidavsky, I., Gross, M. and Unanue, E. R., Presentation on class II MHC molecules of endogenous lysozyme targeted to the endocytic pathway. J. Immunol. 1997. 158: 2670-2679.
4. Sanderson, S., Frauwirth, K. and Shastri, N., Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 1995. 92: 7217-7221.
5. Sponaas, A., Carstens, C. and Koch, N., C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells. Gene Ther. 1999. 6: 1826-1834.
6. van Bergen, J., Schoenberger, S. P., Verreck, F., Amons, R., Offringa, R. and Koning, F., Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc. Natl. Acad. Sci. 1997. 94: 7499-7502.
7. van Bergen, J., Camps, M., Offringa, R., Melief, C. J. M., Ossendorp, F. and Koning, F., Superior tumor protection induced by a cellular vaccine carrying a tumor-specific t helper epitope by genetic exchange of the class II-associated invariant chain peptide. Cancer Res. 2000. 60: 6427-6433.
8. Bonehill, A., Heirman, C., Tuyaerts, S., Michiels, A., Zhang, Y., van der Bruggen, P. and Thielemans, K., Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res. 2003. 63: 5587-5594.
9. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. and Kast, W. M., Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. U. S. A. 1996. 93: 7855-7860.
10. Dutoit, V., Taub, R. N., Papadopoulos, K. P., Talbot, S., Keohan, M. L., Brehm, M., Gnjatic, S. et al., Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest. 2002. 110: 1813-1822.
11. Boczkowski, D., Nair, S. K., Snyder, D. and Gilboa, E., Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996. 184: 465-472.
12. Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H. et al., Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993. 259: 1745-1749.
13. Morel, S., Levy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A. L., Monsarrat, B. et al., Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000. 12: 107-117.
14. Van den Eynde, B. J. and Morel, S., Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr. Opin. Immunol. 2001. 13: 147-153.
15. Basler, M., Lauer, C., Beck, U. and Groettrup, M., The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol. 2009. 183: 6145-6150.
16. Pellicciotta, I., Cortez-Gonzalez, X., Sasik, R., Reiter, Y., Hardiman, G., Langlade-Demoyen, P. and Zanetti, M., Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. Cancer Res. 2008. 68: 8085-8093.
17. Vigna, J. L., Smith, K. D. and Lutz, C. T., Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove. J. Immunol. 1996. 157: 4503-4510.
18. Sugita, M. and Brenner, M. B., Association of the invariant chain with major histocompatibility complex class I molecules directs trafficking to endocytic compartments. J. Biol. Chem. 1995. 270: 1443-1448.
19. Basha, G., Omilusik, K., Chavez-Steenbock, A., Reinicke, A. T., Lack, N., Choi, K. B. and Jefferies, W. A., A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat. Immunol. 2012. 13: 237-245.
20. Holst, P. J., Sorensen, M. R., Mandrup Jensen, C. M., Orskov, C., Thomsen, A. R. and Christensen, J. P., MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J. Immunol. 2008. 180: 3339-3346.
21. Powis, S. J., CLIP-region mediated interaction of invariant chain with MHC class I molecules. FEBS Lett. 2006. 580: 3112-3116.
22. van Luijn, M. M., van de Loosdrecht, A. A., Lampen, M. H., van Veelen, P. A., Zevenbergen, A., Kester, M. G., de Ru, A. H. et al., Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells. PLoS One 2012. 7: e34649.
23. Paul, P., van den Hoorn, T., Jongsma, M. L., Bakker, M. J., Hengeveld, R., Janssen, L., Cresswell, P. et al., A genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell 2011. 145: 268-283.
24. Knight, A. M., Lucocq, J. M., Prescott, A. R., Ponnambalam, S. and Watts, C., Antigen endocytosis and presentation mediated by human membrane IgG1 in the absence of the Ig(alpha)/Ig(beta) dimer. EMBO J. 1997. 16: 3842-3850.
25. van Lith, M., van Ham, M., Griekspoor, A., Tjin, E., Verwoerd, D., Calafat, J., Janssen, H. et al., Regulation of MHC class II antigen presentation by sorting of recycling HLA-DM/DO and class II within the multivesicular body. J. Immunol. 2001. 167: 884-892.
26. Landsverk, O. J., Barois, N., Gregers, T. F. and Bakke, O., Invariant chain increases the half-life of MHC II by delaying endosomal maturation. Immunol. Cell Biol. 2010. 89: 619-629.
27. Nordeng, T. W., Gregers, T. F., Kongsvik, T. L., Méresse, S., Gorvel, J.-P., Jourdan, F., Motta, A. et al., The cytoplasmic tail of invariant chain regulates endosome fusion and morphology. Mol. Biol. Cell 2002. 13: 1846-1856.
28. Skjeldal, F. M., Strunze, S., Bergeland, T., Walseng, E., Gregers, T. F. and Bakke, O., The fusion of early endosomes induces molecular-motor-driven tubule formation and fission. J. Cell Sci. 2012. 125: 1910-1919.
29. Progida, C., Nielsen, M. S., Koster, G., Bucci, C. and Bakke, O., Dynamics of Rab7b-dependent transport of sorting receptors. Traffic 2012. 13: 1273-1285.
30. Hoorn, T., Paul, P., Janssen, L., Janssen, H. and Neefjes, J., Dynamics within tetraspanin pairs affect MHC class II expression. J. Cell Sci. 2012. 125: 328-339.
31. Lizee, G., Basha, G., Tiong, J., Julien, J. P., Tian, M., Biron, K. E. and Jefferies, W. A., Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat. Immunol. 2003. 4: 1065-1073.
32. Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S. et al., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994. 180: 35-42.
33. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V. et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 1998. 160: 1750-1758.
34. Bae, J., Martinson, J. A. and Klingemann, H. G., Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin. Cancer Res. 2005. 11: 1629-1638.
35. Gregers, T. F., Fleckenstein, B., Vartdal, F., Roepstorff, P., Bakke, O. and Sandlie, I., MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. Int. Immunol. 2003. 15: 1291-1299.
36. Abrahamsen, I. W., Kjellevoll, S., Greve-Isdahl, M., Mensali, N., Wälchli, S., Kumari, S., Loland, B. F. et al., T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. Int. J. Cancer 2011. 130: 1821-1832.
37. Stronen, E., Abrahamsen, I. W., Gaudernack, G., Wälchli, S., Munthe, E., Buus, S., Johansen, F. E. et al., Dendritic cells engineered to express defined Allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells. Scand. J. Immunol. 2009. 69: 319-328.
38. Rubio, V., Stuge, T. B., Singh, N., Betts, M. R., Weber, J. S., Roederer, M. and Lee, P. P., Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 2003. 9: 1377-1382.
39. Koppers-Lalic, D., Reits, E. A. J., Ressing, M. E., Lipinska, A. D., Abele, R., Koch, J., Rezende, M. M. et al., Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc. Natl. Acad. Sci. U. S. A. 2005. 102: 5144-5149.
40. Rimoldi, D., Muehlethaler, K., Salvi, S., Valmori, D., Romero, P., Cerottini, J. C. and Levy, F., Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope. J. Biol. Chem. 2001. 276: 43189-43196.
41. Chapatte, L., Servis, C., Valmori, D., Burlet-Schiltz, O., Dayer, J., Monsarrat, B., Romero, P. et al., Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. J. Immunol. 2004. 173: 6033-6040.
42. Salter, R. D. and Cresswell, P., Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 1986. 5: 943-949.
43. Salter, R. D., Howell, D. N. and Cresswell, P., Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985. 21: 235-246.
44. Abrahamsen, I. W., Stronen, E., Walchli, S., Johansen, J. N., Kjellevoll, S., Kumari, S., Komada, M. et al., Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 2010. 24: 1901-1909.
45. Gorvel, J. P., Escola, J. M., Stang, E. and Bakke, O., Invariant chain induces a delayed transport from early to late endosomes. J. Biol. Chem. 1995. 270: 2741-2746.
46. Carstens, C., Newman, D. K., Bohlen, H., Konig, A. and Koch, N., Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation. Int. Immunol. 2000. 12: 1561-1568.
47. Sorensen, M. R., Holst, P. J., Pircher, H., Christensen, J. P. and Thomsen, A. R., Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+ T-cell-independent CD8+ T-cell-mediated tumor control. Eur. J. Immunol. 2009. 39: 2725-2736.
48. Sorensen, M. R., Holst, P. J., Steffensen, M. A., Christensen, J. P. and Thomsen, A. R., Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010. 28: 6757-6764.
49. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G. et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007. 13: 1050-1059.
50. Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S. et al., Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol. Ther. 2010. 18: 135-142.
51. Gregers, T. F., Nordeng, T. W., Birkeland, H. C., Sandlie, I. and Bakke, O., The cytoplasmic tail of invariant chain modulates antigen processing and presentation. Eur. J. Immunol. 2003. 33: 277-286.
52. Saeboe-Larssen, S., Fossberg, E. and Gaudernack, G., mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J. Immunol. Methods 2002. 259: 191-203.
53. Walchli, S., Loset, G. A., Kumari, S., Johansen, J. N., Yang, W., Sandlie, I. and Olweus, J., A practical approach to T-cell receptor cloning and expression. PLoS One 2011. 6: e27930.
54. Toebes, M., Rodenko, B., Ovaa, H. and Schumacher, T. N., Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr. Prot. Immunol. 2009. 18: 16.
55. Shen, X. Z., Billet, S., Lin, C., Okwan-Duodu, D., Chen, X., Lukacher, A. E. and Bernstein, K. E., The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat. Immunol. 12: 1078-1085.